The role of A2AR antagonists has been evaluated in several rodent PD models, in which it dose-dependently increases motor activity, when combined with L-DOPA and D2R agonists at sub-threshold doses; Also, Parkinson-related motor symptoms have been consistently treated in rodents and non-human primates following administration of A2AR antagonists (Ferré and Fuxe, 1992; Tanganelli et al., 2004; Schwarzschild et al., 2006; Fuxe et al., 2007). Here, ADORA2A is linked to Parkinson disease.